ECB-ART-51209
Curr Oncol
2022 Oct 16;2910:7816-7831. doi: 10.3390/curroncol29100618.
Show Gene links
Show Anatomy links
Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer.
Xiang Y
,
Zhang S
,
Fang X
,
Jiang Y
,
Fang T
,
Liu J
,
Lu K
.
???displayArticle.abstract???
Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases and is the leading cause of cancer-related death. Despite advances in chemotherapy and immunotherapy, the prognosis for advanced patients remains poor. The discovery of oncogenic driver mutations, such as anaplastic lymphoma kinase (ALK) mutations, means that a subset of patients has opportunities for targeted therapy. With the improvement of genetic testing coverage, more and more ALK fusion subtypes and ALK partners have been discovered, and more than 90 rare ALK fusion subtypes have been found in NSCLC. However, unlike the common fusion, echinoderm microtubule-associated protein-like 4 (EML4)-ALK, some rare ALK fusions such as striatin (STRN)-ALK and huntingtin interacting protein 1 (HIP1)-ALK, etc., the large-scale clinical data related to its efficacy are still immature. The clinical application of ALK-tyrosine kinase inhibitors (ALK-TKIs) mainly depends on the positivity of the ALK gene, regardless of the molecular characteristics of the fusion partner. Recent clinical studies in the ALK-positive NSCLC population have demonstrated differences in progression-free survival (PFS) among patients based on different ALK fusion subtypes. This article will introduce the biological characteristics of ALK fusion kinase and common detection methods of ALK fusion and focus on summarizing the differential responses of several rare ALK fusions to ALK-TKIs, and propose corresponding treatment strategies, so as to better guide the application of ALK-TKIs in rare ALK fusion population.
???displayArticle.pubmedLink??? 36290895
???displayArticle.link??? Curr Oncol
References [+] :
Bordi,
Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment.
2017, Pubmed
Bordi, Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment. 2017, Pubmed
Bunting, End-joining, translocations and cancer. 2013, Pubmed
Camidge, Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. 2021, Pubmed
Camidge, Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study. 2019, Pubmed , Echinobase
Camidge, Crizotinib in Patients With MET-Amplified NSCLC. 2021, Pubmed
Cao, NCOA1-ALK: a novel ALK rearrangement in one lung adenocarcinoma patient responding to crizotinib treatment. 2019, Pubmed
Chang, Clinicopathological features and diagnostic methods of ALK fusion‑positive non‑small cell lung cancer in Korea. 2020, Pubmed
Chen, ALKAL1 gene silencing prevents colorectal cancer progression via suppressing Sonic Hedgehog (SHH) signaling pathway. 2021, Pubmed
Chen, Mutation L1196M-induced conformational changes and the drug resistant mechanism of anaplastic lymphoma kinase studied by free energy perturbation and umbrella sampling. 2017, Pubmed
Chen, A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib. 2020, Pubmed
Couëtoux du Tertre, Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes. 2019, Pubmed
Cutz, Canadian anaplastic lymphoma kinase study: a model for multicenter standardization and optimization of ALK testing in lung cancer. 2014, Pubmed
Dagogo-Jack, MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer. 2020, Pubmed
Du, ALK-rearrangement in non-small-cell lung cancer (NSCLC). 2018, Pubmed
Du, High STRN Expression Promotes HCC Invasion and Migration but Not Cell Proliferation or Apoptosis through Facilitating Epithelial-Mesenchymal Transition. 2020, Pubmed
Du, CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib. 2018, Pubmed
Ducray, The Transcriptional Roles of ALK Fusion Proteins in Tumorigenesis. 2019, Pubmed
Evangelista, Detection of ALK fusion transcripts in FFPE lung cancer samples by NanoString technology. 2017, Pubmed
Fang, HIP1-ALK, a novel ALK fusion variant that responds to crizotinib. 2014, Pubmed
Fang, MPRIP-ALK, a Novel ALK Rearrangement That Responds to ALK Inhibition in NSCLC. 2019, Pubmed
Fontana, Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK. 2015, Pubmed
Fukui, Review of Therapeutic Strategies for Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer. 2022, Pubmed
Gainor, Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. 2016, Pubmed
Gerboth, Phosphorylation of SOS1 on tyrosine 1196 promotes its RAC GEF activity and contributes to BCR-ABL leukemogenesis. 2018, Pubmed
Golding, The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC). 2018, Pubmed
Gottfried, The Sla2p/HIP1/HIP1R family: similar structure, similar function in endocytosis? 2010, Pubmed
Guo, A rare double ALK fusion variant EML4-ALK and CDK15-ALK in lung adenocarcinoma and response to crizotinib: A case report. 2020, Pubmed
Hallberg, Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. 2013, Pubmed
Hastings, Mechanisms of change in gene copy number. 2009, Pubmed
Heeke, Detection of ALK fusion transcripts in plasma of non-small cell lung cancer patients using a novel RT-PCR based assay. 2021, Pubmed
Heuckmann, Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. 2012, Pubmed
Hillig, Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction. 2019, Pubmed
Hirai, Monomerization of ALK Fusion Proteins as a Therapeutic Strategy in ALK-Rearranged Non-small Cell Lung Cancers. 2020, Pubmed , Echinobase
Hirsch, New and emerging targeted treatments in advanced non-small-cell lung cancer. 2016, Pubmed
Hong, HIP1-ALK, a novel fusion protein identified in lung adenocarcinoma. 2014, Pubmed , Echinobase
Hout, Performance of a RT-PCR Assay in Comparison to FISH and Immunohistochemistry for the Detection of ALK in Non-Small Cell Lung Cancer. 2017, Pubmed
Hsu, Huntingtin-Interacting Protein-1 Is an Early-Stage Prognostic Biomarker of Lung Adenocarcinoma and Suppresses Metastasis via Akt-mediated Epithelial-Mesenchymal Transition. 2016, Pubmed
Jang, Custom Gene Capture and Next-Generation Sequencing to Resolve Discordant ALK Status by FISH and IHC in Lung Adenocarcinoma. 2016, Pubmed , Echinobase
Kalchman, HIP1, a human homologue of S. cerevisiae Sla2p, interacts with membrane-associated huntingtin in the brain. 1997, Pubmed
Kang, Clinicopathological features and resistance mechanisms in HIP1-ALK-rearranged lung cancer: A multicenter study. 2022, Pubmed , Echinobase
Karachaliou, Optimal detection of ALK rearranged lung adenocarcinomas. 2013, Pubmed
Katayama, Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine. 2015, Pubmed
Katayama, P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer. 2016, Pubmed
Kelly, Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. 2014, Pubmed
Kemps, ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition. 2022, Pubmed
Kong, Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK). 2019, Pubmed
Krawczyk, Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement. 2021, Pubmed
Kusano, Two Cases of Renal Cell Carcinoma Harboring a Novel STRN-ALK Fusion Gene. 2016, Pubmed
Kwon, Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors. 2022, Pubmed
Lasota, Colorectal Adenocarcinomas Harboring ALK Fusion Genes: A Clinicopathologic and Molecular Genetic Study of 12 Cases and Review of the Literature. 2020, Pubmed
Lazzari, Targeting ALK in patients with advanced non small cell lung cancer: biology, diagnostic and therapeutic options. 2014, Pubmed
Li, A novel HIP1-ALK fusion variant in lung adenocarcinoma showing resistance to Crizotinib. 2021, Pubmed
Li, Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC. 2021, Pubmed
Li, Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review. 2021, Pubmed
Li, High efficacy of alectinib in a patient with advanced lung adenocarcinoma with 2 rare ALK fusion sites: a case report. 2022, Pubmed
Lim, Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer. 2017, Pubmed
Lin, Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing. 2021, Pubmed
Lin, A Novel EML6-ALK FBXO11-ALK Double Fusion Variant in Lung Adenocarcinoma and Response to Crizotinib. 2018, Pubmed
Lipson, Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. 2012, Pubmed
Luo, Coexistence of a Novel PRKCB-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient and Response to Crizotinib. 2019, Pubmed
Maddalo, In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. 2014, Pubmed , Echinobase
Majewski, Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing. 2013, Pubmed
Mano, Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer. 2008, Pubmed , Echinobase
Medves, Multiple oligomerization domains of KANK1-PDGFRβ are required for JAK2-independent hematopoietic cell proliferation and signaling via STAT5 and ERK. 2011, Pubmed
Medves, Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies. 2012, Pubmed
Mino-Kenudson, A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. 2010, Pubmed
Mizuta, Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer. 2021, Pubmed
Murakami, A Screening Method for the ALK Fusion Gene in NSCLC. 2012, Pubmed , Echinobase
Murray, Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK. 2015, Pubmed
Nagasaka, STRN-ALK, A Novel In-Frame Fusion With Response to Alectinib. 2021, Pubmed
Nakanishi, Case Report of Non-Small Cell Lung Cancer with STRN-ALK Translocation: A Nonresponder to Alectinib. 2017, Pubmed
Naumann, Fusion of PDGFRB to MPRIP, CPSF6, and GOLGB1 in three patients with eosinophilia-associated myeloproliferative neoplasms. 2015, Pubmed
Niu, Anaplastic Lymphoma Kinase Testing: IHC vs. FISH vs. NGS. 2017, Pubmed
Ou, Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib. 2014, Pubmed
Ou, Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. 2012, Pubmed
Panebianco, Characterization of thyroid cancer driven by known and novel ALK fusions. 2019, Pubmed
Park, Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. 2012, Pubmed
Pérot, Identification of a recurrent STRN/ALK fusion in thyroid carcinomas. 2014, Pubmed
Qin, Rare GCC2-ALK fusion G13:A20 detected by next generation sequencing in non-small cell lung cancer patients and treatment response. 2019, Pubmed
Qin, Identification of a Novel EML4-ALK, BCL11A-ALK Double-Fusion Variant in Lung Adenocarcinoma Using Next-Generation Sequencing and Response to Crizotinib. 2019, Pubmed
Richards, Microtubule association of EML proteins and the EML4-ALK variant 3 oncoprotein require an N-terminal trimerization domain. 2015, Pubmed , Echinobase
Sampson, A Polytherapy Strategy Using Vincristine and ALK Inhibitors to Sensitise EML4-ALK-Positive NSCLC. 2022, Pubmed
Serra-Marques, Concerted action of kinesins KIF5B and KIF13B promotes efficient secretory vesicle transport to microtubule plus ends. 2020, Pubmed
Shaw, Tyrosine kinase gene rearrangements in epithelial malignancies. 2013, Pubmed
Solomon, Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014. 2016, Pubmed
Song, Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance. 2015, Pubmed
Stoica, Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. 2002, Pubmed
Stransky, The landscape of kinase fusions in cancer. 2014, Pubmed
Su, STRN-ALK Fusion in Lung Adenocarcinoma with Excellent Response Upon Alectinib Treatment: A Case Report and Literature Review. 2020, Pubmed
Takeuchi, KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. 2009, Pubmed
Tang, Fluorescence in Situ Hybridization (FISH) for Detecting Anaplastic Lymphoma Kinase (ALK) Rearrangement in Lung Cancer: Clinically Relevant Technical Aspects. 2019, Pubmed
Tao, Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively. 2022, Pubmed
Teixidó, Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements. 2014, Pubmed , Echinobase
Tian, Unique molecular features and clinical outcomes in young patients with non-small cell lung cancer harboring ALK fusion genes. 2020, Pubmed
Uçkun, In vivo Profiling of the Alk Proximitome in the Developing Drosophila Brain. 2021, Pubmed
Vaishnavi, Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. 2013, Pubmed
Vendrell, Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches. 2017, Pubmed
Wiesner, Alternative transcription initiation leads to expression of a novel ALK isoform in cancer. 2015, Pubmed
Wolfstetter, Identification of the Wallenda JNKKK as an Alk suppressor reveals increased competitiveness of Alk-expressing cells. 2020, Pubmed
Wong, A novel KIF5B-ALK variant in nonsmall cell lung cancer. 2011, Pubmed , Echinobase
Wu, Coexistence of a novel CCNY-ALK and ATIC-ALK double-fusion in one patient with ALK-positive NSCLC and response to crizotinib: a case report. 2020, Pubmed
Wu, Novel NLRC4-ALK and EML4-ALK double fusion mutations in a lung adenocarcinoma patient: A case report. 2020, Pubmed
Yakirevich, Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target. 2016, Pubmed
Yanagitani, Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms. 2020, Pubmed
Yang, A Rare STRN-ALK Fusion in Lung Adenocarcinoma Identified Using Next-Generation Sequencing-Based Circulating Tumor DNA Profiling Exhibits Excellent Response to Crizotinib. 2017, Pubmed
Yin, Reporting on Two Novel Fusions, DYSF-ALK and ITGAV-ALK, Coexisting in One Patient with Adenocarcinoma of Lung, Sensitive to Crizotinib. 2018, Pubmed
Yoshida, Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer. 2016, Pubmed
Yu, Effect of multiple cycles of freeze-thawing on the RNA quality of lung cancer tissues. 2017, Pubmed
Zeng, Coexistence of a secondary STRN-ALK, EML4-ALK double-fusion variant in a lung adenocarcinoma patient with EGFR mutation: a case report. 2021, Pubmed
Zeng, Case Report: Identification of Two Rare Fusions, PDK1-ALK and STRN-ALK, That Coexist in a Lung Adenocarcinoma Patient and the Response to Alectinib. 2021, Pubmed
Zeng, A rare KIF5B-ALK fusion variant in a lung adenocarcinoma patient who responded to crizotinib and acquired the ALK L1196M mutation after resistance: a case report. 2021, Pubmed
Zhai, Case Report: A Novel Non-Reciprocal ALK Fusion: ALK-GCA and EML4-ALK Were Identified in Lung Adenocarcinoma, Which May Respond to Alectinib Adjuvant-Targeted Therapy. 2021, Pubmed
Zhao, A Case of Simultaneously Diagnosed Lung Adenocarcinoma and Endobronchial Inflammatory Myofibroblastic Tumor with Two Distinct Types of ALK Translocation. 2021, Pubmed
Zhou, Responder of Gefitinib Plus Crizotinib in Osimertinib Failure EGFR-mutant NSCLC-Resistant With Newly Identified STRN-ALK by Next-Generation Sequencing. 2019, Pubmed